TY - JOUR
T1 - Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy
AU - Schultz, Luciana
AU - Albadine, Roula
AU - Hicks, Jessica
AU - Jadallah, Sana
AU - Demarzo, Angelo M.
AU - Chen, Ying Bei
AU - Neilsen, Matthew E.
AU - Gonzalgo, Mark L.
AU - Sidransky, David
AU - Schoenberg, Mark
AU - Netto, George J.
PY - 2010/12/1
Y1 - 2010/12/1
N2 - Background: Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is crucial. Mammalian target of rapamycin (mTOR) pathway plays a pivotal role in establishing cell shape, migration, and proliferation. Methods: Tissue microarrays were constructed from 132 cystectomies (1994-2002). Immunohistochemistry was performed for Pten, c-myc, p27, phosphorylated (phos)Akt, phosS6, and 4E-BP1. Markers were evaluated for pattern, percentage, and intensity of staining. Results: Mean length of follow-up was 62.6 months (range, 1-182 months). Disease progression, overall survival (OS), and disease-specific survival (DSS) rates were 42%, 60%, and 68%, respectively. Pten showed loss of expression in 35% of bladder urothelial carcinoma. All markers showed lower expression in invasive bladder urothelial carcinoma compared with benign urothelium with the exception of 4E-BP1. Pten, p27, phosAkt, phosS6, and 4E-BP1 expression correlated with pathologic stage (pathological stage; P<.03). Pten, 4E-BP1, and phosAkt expression correlated with divergent aggressive histology and invasion. phosS6 expression inversely predicted OS (P =.01), DSS (P =.001), and progression (P =.05). c-myc expression inversely predicted progression (P =.01). In a multivariate analysis model that included TNM stage grouping, divergent aggressive histology, concomitant carcinoma in situ, phosS6, and c-myc expression, phosS6 was an independent predictor of DSS (P =.03; hazard ratio [HR], -0.19), whereas c-myc was an independent predictor of progression (P =.02; HR, -0.38). In a second model substituting organ-confined disease and lymph node status for TNM stage grouping, phosS6 and c-myc remained independent predictors of DSS (P =.03; HR, -0.21) and progression (P =.03; HR, -0.34), respectively. Conclusions: We found an overall down-regulation of mTOR pathway in bladder urothelial carcinoma. phosS6 independently predicted DSS, and c-myc independently predicted progression. Cancer 2010. © 2010 American Cancer Society. Mammalian target of rapamycin pathway was overall down-regulated in urothelial carcinoma. Phosphorylated S6 protein was an independent predictor of disease-specific survival, and c-myc was an independent predictor of progression.
AB - Background: Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is crucial. Mammalian target of rapamycin (mTOR) pathway plays a pivotal role in establishing cell shape, migration, and proliferation. Methods: Tissue microarrays were constructed from 132 cystectomies (1994-2002). Immunohistochemistry was performed for Pten, c-myc, p27, phosphorylated (phos)Akt, phosS6, and 4E-BP1. Markers were evaluated for pattern, percentage, and intensity of staining. Results: Mean length of follow-up was 62.6 months (range, 1-182 months). Disease progression, overall survival (OS), and disease-specific survival (DSS) rates were 42%, 60%, and 68%, respectively. Pten showed loss of expression in 35% of bladder urothelial carcinoma. All markers showed lower expression in invasive bladder urothelial carcinoma compared with benign urothelium with the exception of 4E-BP1. Pten, p27, phosAkt, phosS6, and 4E-BP1 expression correlated with pathologic stage (pathological stage; P<.03). Pten, 4E-BP1, and phosAkt expression correlated with divergent aggressive histology and invasion. phosS6 expression inversely predicted OS (P =.01), DSS (P =.001), and progression (P =.05). c-myc expression inversely predicted progression (P =.01). In a multivariate analysis model that included TNM stage grouping, divergent aggressive histology, concomitant carcinoma in situ, phosS6, and c-myc expression, phosS6 was an independent predictor of DSS (P =.03; hazard ratio [HR], -0.19), whereas c-myc was an independent predictor of progression (P =.02; HR, -0.38). In a second model substituting organ-confined disease and lymph node status for TNM stage grouping, phosS6 and c-myc remained independent predictors of DSS (P =.03; HR, -0.21) and progression (P =.03; HR, -0.34), respectively. Conclusions: We found an overall down-regulation of mTOR pathway in bladder urothelial carcinoma. phosS6 independently predicted DSS, and c-myc independently predicted progression. Cancer 2010. © 2010 American Cancer Society. Mammalian target of rapamycin pathway was overall down-regulated in urothelial carcinoma. Phosphorylated S6 protein was an independent predictor of disease-specific survival, and c-myc was an independent predictor of progression.
KW - 4E-BP1
KW - Akt
KW - Pten
KW - bladder
KW - c-myc
KW - mammalian target of rapamycin
KW - p27
KW - phosS6
KW - urothelial carcinoma
UR - http://www.scopus.com/inward/record.url?scp=78649556380&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78649556380&partnerID=8YFLogxK
U2 - 10.1002/cncr.25502
DO - 10.1002/cncr.25502
M3 - Article
C2 - 20939013
AN - SCOPUS:78649556380
SN - 0008-543X
VL - 116
SP - 5517
EP - 5526
JO - Cancer
JF - Cancer
IS - 23
ER -